New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Name: New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study
Uploaded: 2016-11-22T04:00:00+00:00
Duration: 5 min 36 s
Description: AHA 2016 The ORION-1 study evaluated different doses of inclisiran, which prevents hepatic PCSK9 production by RNA interference. With a single injection, a

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Cardiology
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Javier Morales, MD, FACP, FACE
- Javier Morales, MD, FACP, FACE
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Nicholas Marston, MD
- Nicholas Marston, MD
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Hyperlipidemia
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Nihar R. Desai, MD, MPH
- Nihar R. Desai, MD, MPH
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Hyperlipidemia
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Matthew Jay Budoff, MD
- Matthew Jay Budoff, MD

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Recommended

Title